PL3228313T3 - Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureniny - Google Patents
Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureninyInfo
- Publication number
- PL3228313T3 PL3228313T3 PL17170079T PL17170079T PL3228313T3 PL 3228313 T3 PL3228313 T3 PL 3228313T3 PL 17170079 T PL17170079 T PL 17170079T PL 17170079 T PL17170079 T PL 17170079T PL 3228313 T3 PL3228313 T3 PL 3228313T3
- Authority
- PL
- Poland
- Prior art keywords
- chlorokynurenine
- dosage forms
- therapeutic uses
- therapeutic
- dosage
- Prior art date
Links
- HQLHZNDJQSRKDT-QMMMGPOBSA-N (2s)-2-amino-4-(2-amino-4-chlorophenyl)-4-oxobutanoic acid Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=C(Cl)C=C1N HQLHZNDJQSRKDT-QMMMGPOBSA-N 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Quinoline Compounds (AREA)
- Cosmetics (AREA)
- Lubricants (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361849191P | 2013-01-22 | 2013-01-22 | |
| EP14743570.5A EP2948140B1 (en) | 2013-01-22 | 2014-01-22 | Dosage forms and therapeutic uses l-4-chlorokynurenine |
| PCT/US2014/012598 WO2014116739A1 (en) | 2013-01-22 | 2014-01-22 | Dosage forms and therapeutic uses l-4-chlorokynurenine |
| EP17170079.2A EP3228313B1 (en) | 2013-01-22 | 2014-01-22 | Dosage forms and therapeutic uses of l-4-chlorokynurenine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3228313T3 true PL3228313T3 (pl) | 2020-03-31 |
Family
ID=51228003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17170079T PL3228313T3 (pl) | 2013-01-22 | 2014-01-22 | Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureniny |
| PL19196366.9T PL3598971T3 (pl) | 2013-01-22 | 2014-01-22 | Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureniny |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19196366.9T PL3598971T3 (pl) | 2013-01-22 | 2014-01-22 | Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureniny |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US9993450B2 (OSRAM) |
| EP (4) | EP3228313B1 (OSRAM) |
| JP (5) | JP6436913B2 (OSRAM) |
| KR (5) | KR20210149905A (OSRAM) |
| CN (4) | CN112933073A (OSRAM) |
| AU (5) | AU2014209466B2 (OSRAM) |
| BR (1) | BR112015017535A2 (OSRAM) |
| CA (3) | CA3128321C (OSRAM) |
| CY (1) | CY1122403T1 (OSRAM) |
| DK (3) | DK2948140T3 (OSRAM) |
| ES (3) | ES2980120T3 (OSRAM) |
| HK (1) | HK1217170A1 (OSRAM) |
| HR (2) | HRP20240812T1 (OSRAM) |
| HU (1) | HUE067381T2 (OSRAM) |
| IL (3) | IL291831A (OSRAM) |
| MX (2) | MX375318B (OSRAM) |
| PL (2) | PL3228313T3 (OSRAM) |
| PT (3) | PT3228313T (OSRAM) |
| RS (1) | RS59687B1 (OSRAM) |
| SI (2) | SI3228313T1 (OSRAM) |
| WO (1) | WO2014116739A1 (OSRAM) |
| ZA (2) | ZA201505569B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210149905A (ko) | 2013-01-22 | 2021-12-09 | 비스타젠 쎄라퓨틱스, 인크. | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
| EA201792571A1 (ru) * | 2015-05-22 | 2018-06-29 | Вистаджен Терапьютикс, Инк. | Терапевтическое применение l-4-хлорокинуренина |
| US20180327351A1 (en) * | 2015-09-08 | 2018-11-15 | Cephalon, Inc. | Prodrugs of chlorokynurenines |
| CN112236412B (zh) | 2018-02-09 | 2024-01-30 | 维斯塔津治疗公司 | 4-氯代犬尿氨酸及中间体的合成 |
| CN109223785A (zh) * | 2018-10-29 | 2019-01-18 | 中国药科大学 | 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用 |
| WO2022082100A1 (en) * | 2020-10-16 | 2022-04-21 | Vistagen Therapeutics, Inc. | Cocrystals of l-4-chlorokynurenine, compositions and therapeutic uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| US5484814A (en) | 1991-02-28 | 1996-01-16 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| US5360814A (en) | 1991-02-28 | 1994-11-01 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| TW518218B (en) | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| AU2002329799B2 (en) | 2001-08-20 | 2007-03-15 | Maiken Nedergaard | Treatment of glial tumors with glutamate antagonists |
| JP2006502158A (ja) | 2002-09-06 | 2006-01-19 | デュレクト コーポレーション | グルタメート媒介神経伝達のモジュレーターの内耳への送達 |
| US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| EA200802054A1 (ru) | 2006-04-12 | 2009-04-28 | Пробиодруг Аг | Ингибиторы фермента |
| EP1903028A1 (en) * | 2006-09-22 | 2008-03-26 | Werner Tschollar | Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects |
| US8058243B2 (en) | 2006-10-13 | 2011-11-15 | Hsc Research And Development Limited Partnership | Method for treating a brain cancer with ifenprodil |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| WO2009135091A1 (en) * | 2008-04-30 | 2009-11-05 | Medivation Technologies, Inc. | Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions |
| CN102159077A (zh) * | 2008-08-21 | 2011-08-17 | 吉瑞工厂 | 用于治疗神经性疼痛的方法 |
| PT2421519T (pt) | 2009-04-23 | 2017-01-26 | Univ Zuerich | Bloqueadores do recetor nmda para o tratamento de anemia falciforme |
| WO2010147938A2 (en) * | 2009-06-17 | 2010-12-23 | Targacept, Inc. | Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands |
| US8951739B2 (en) | 2009-08-12 | 2015-02-10 | Human Metabolome Technologies Inc. | Biomarker for depression, method for measuring a biomarker for depression, computer program, and recording medium |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| EP2338873A1 (en) * | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
| BR112012031836A2 (pt) | 2010-06-15 | 2016-11-08 | Gruenenthal Gmbh | combinação farmacêutica para o tratamento da dor |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| KR20210149905A (ko) | 2013-01-22 | 2021-12-09 | 비스타젠 쎄라퓨틱스, 인크. | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
| JP2016513718A (ja) | 2013-03-14 | 2016-05-16 | ヴィスタゲン セラピューティクス、インコーポレイテッド | キラルキヌレニン化合物及び中間体の合成 |
| WO2015065891A1 (en) | 2013-10-28 | 2015-05-07 | Naurex, Inc. | Nmda receptor modulators and prodrugs, salts, and uses thereof |
| EA201792571A1 (ru) | 2015-05-22 | 2018-06-29 | Вистаджен Терапьютикс, Инк. | Терапевтическое применение l-4-хлорокинуренина |
-
2014
- 2014-01-22 KR KR1020217039478A patent/KR20210149905A/ko not_active Ceased
- 2014-01-22 SI SI201431410T patent/SI3228313T1/sl unknown
- 2014-01-22 HR HRP20240812TT patent/HRP20240812T1/hr unknown
- 2014-01-22 CN CN202110387961.2A patent/CN112933073A/zh active Pending
- 2014-01-22 CA CA3128321A patent/CA3128321C/en active Active
- 2014-01-22 PT PT171700792T patent/PT3228313T/pt unknown
- 2014-01-22 CN CN201480010060.XA patent/CN105073108A/zh active Pending
- 2014-01-22 IL IL291831A patent/IL291831A/en unknown
- 2014-01-22 MX MX2015009277A patent/MX375318B/es active IP Right Grant
- 2014-01-22 DK DK14743570.5T patent/DK2948140T3/en active
- 2014-01-22 BR BR112015017535A patent/BR112015017535A2/pt not_active IP Right Cessation
- 2014-01-22 CA CA3216579A patent/CA3216579A1/en active Pending
- 2014-01-22 PT PT191963669T patent/PT3598971T/pt unknown
- 2014-01-22 EP EP17170079.2A patent/EP3228313B1/en active Active
- 2014-01-22 SI SI201432078T patent/SI3598971T1/sl unknown
- 2014-01-22 EP EP24164414.5A patent/EP4385563A3/en active Pending
- 2014-01-22 HK HK16105132.0A patent/HK1217170A1/zh unknown
- 2014-01-22 PL PL17170079T patent/PL3228313T3/pl unknown
- 2014-01-22 AU AU2014209466A patent/AU2014209466B2/en active Active
- 2014-01-22 ES ES19196366T patent/ES2980120T3/es active Active
- 2014-01-22 CN CN202110387953.8A patent/CN113209068A/zh active Pending
- 2014-01-22 DK DK19196366.9T patent/DK3598971T3/da active
- 2014-01-22 WO PCT/US2014/012598 patent/WO2014116739A1/en not_active Ceased
- 2014-01-22 HU HUE19196366A patent/HUE067381T2/hu unknown
- 2014-01-22 KR KR1020157022405A patent/KR102257284B1/ko active Active
- 2014-01-22 ES ES14743570.5T patent/ES2635353T3/es active Active
- 2014-01-22 JP JP2015553921A patent/JP6436913B2/ja active Active
- 2014-01-22 KR KR1020217015432A patent/KR102335919B1/ko active Active
- 2014-01-22 DK DK17170079T patent/DK3228313T3/da active
- 2014-01-22 PT PT147435705T patent/PT2948140T/pt unknown
- 2014-01-22 KR KR1020237021428A patent/KR20230098711A/ko not_active Ceased
- 2014-01-22 EP EP14743570.5A patent/EP2948140B1/en active Active
- 2014-01-22 US US14/762,015 patent/US9993450B2/en active Active
- 2014-01-22 CN CN202110384159.8A patent/CN113116877A/zh active Pending
- 2014-01-22 RS RS20191519A patent/RS59687B1/sr unknown
- 2014-01-22 PL PL19196366.9T patent/PL3598971T3/pl unknown
- 2014-01-22 CA CA2898619A patent/CA2898619C/en active Active
- 2014-01-22 EP EP19196366.9A patent/EP3598971B1/en active Active
- 2014-01-22 KR KR1020227044517A patent/KR20230003410A/ko not_active Ceased
- 2014-01-22 ES ES17170079T patent/ES2751138T3/es active Active
-
2015
- 2015-07-17 MX MX2020009966A patent/MX2020009966A/es unknown
- 2015-07-22 IL IL240090A patent/IL240090B/en active IP Right Grant
- 2015-08-03 ZA ZA2015/05569A patent/ZA201505569B/en unknown
-
2016
- 2016-02-08 US US15/018,219 patent/US9993453B2/en active Active
- 2016-11-02 ZA ZA2016/07581A patent/ZA201607581B/en unknown
-
2018
- 2018-05-14 US US15/978,855 patent/US10632091B2/en active Active
- 2018-06-08 US US16/003,816 patent/US10980758B2/en active Active
- 2018-06-08 US US16/003,793 patent/US10617663B2/en active Active
- 2018-06-08 US US16/003,804 patent/US20180369180A1/en not_active Abandoned
- 2018-09-13 JP JP2018171786A patent/JP6804497B2/ja active Active
- 2018-10-26 AU AU2018253600A patent/AU2018253600B2/en active Active
-
2019
- 2019-11-27 CY CY20191101244T patent/CY1122403T1/el unknown
- 2019-12-04 HR HRP20192189TT patent/HRP20192189T1/hr unknown
-
2020
- 2020-07-01 AU AU2020204420A patent/AU2020204420A1/en not_active Abandoned
- 2020-07-03 JP JP2020115273A patent/JP7021298B2/ja active Active
- 2020-07-16 IL IL276126A patent/IL276126B/en unknown
-
2022
- 2022-02-03 JP JP2022015622A patent/JP2022070894A/ja active Pending
- 2022-06-21 US US17/845,105 patent/US12036198B2/en active Active
- 2022-08-22 AU AU2022221382A patent/AU2022221382B2/en active Active
-
2024
- 2024-02-27 JP JP2024027330A patent/JP2024069257A/ja active Pending
- 2024-03-21 US US18/611,908 patent/US20250161251A1/en active Pending
- 2024-12-18 AU AU2024278564A patent/AU2024278564A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287516A (en) | Medicinal uses of empagliflozin | |
| IL273688A (en) | Evaluation and treatment of bradykinin-mediated disorders | |
| IL270347B (en) | Therapeutically active compounds and methods of use | |
| IL286759A (en) | Therapeutic methods and preparations | |
| IL241101A0 (en) | Medicinal uses of empagliflozin | |
| GB201320729D0 (en) | Therapeutic compounds and their use | |
| IL241102A0 (en) | Medicinal uses of empagliflozin | |
| ZA201600667B (en) | Therapeutically active compounds and their methods of use | |
| PL2981271T3 (pl) | Zastosowania terapeutyczne empagliflozyny | |
| SG11201508167PA (en) | Therapeutic compositions and uses thereof | |
| GB201311361D0 (en) | Compounds and their therapeutic use | |
| ZA201607581B (en) | Dosage forms and therapeutic uses l-4lchlorokynurenine | |
| GB201308736D0 (en) | Compounds and their therapeutic use | |
| GB201317804D0 (en) | Therapeutic compounds and their use | |
| GB201316173D0 (en) | Compounds and their therapeutic use | |
| GB201307677D0 (en) | Compounds and their therapeutic use | |
| GB201319255D0 (en) | Therapeutic compositions and methods | |
| GB201319595D0 (en) | Combination of Analgesic drugs | |
| GB201316468D0 (en) | Combination of analgesic drugs |